KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) has announced that five of its abstracts have been accepted for e-Poster presentations at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI), scheduled to be held in Boston, MA, from October 24-28. The details of the presentations are as follows:
- Patient-Reported Anxiety Impacts Utilization of Injectable On-demand Treatment of Hereditary Angioedema Attacks
Authors: Cristine Radojicic, Autumn Burnette, Sally van Kooten, Neil Malloy, Markus Heckmann, Hilary Longhurst
Presentation Date & Time: Friday, October 25 at 2:00 PM ET
Location: Monitor 20, Exhibit Hall A - On-demand Treatment of Laryngeal Hereditary Angioedema Attacks with Sebetralstat: Pooled Analysis from KONFIDENT and KONFIDENT-S
Authors: Emel Aygören-Pürsün, Jonathan A. Bernstein, William R. Lumry, Paul K. Audhya, James Hao, Michael D. Smith, Christopher M. Yea, Marc A. Riedl
Presentation Date & Time: Friday, October 25 at 5:00 PM ET
Location: Monitor 20, Exhibit Hall A - Substantial Reduction of Hereditary Angioedema Attack Symptom Burden in the Sebetralstat Phase 3 KONFIDENT Trial
Authors: William R. Lumry, Danny M. Cohn, Jonathan A. Bernstein, Paul K. Audhya, James Hao, Michael D. Smith, Christopher M. Yea, Marc A. Riedl
Presentation Date & Time: Friday, October 25 at 5:00 PM ET
Location: Monitor 19, Exhibit Hall A - Indirect Treatment Comparison of Oral Sebetralstat and Intravenous rhC1-INH as On-demand Treatments for Hereditary Angioedema
Authors: H. Henry Li, Markus Magerl, Timothy Craig, Michael E. Manning, Noemi Hummel, Alice Wang, Paul K. Audhya, Jonathan A. Bernstein
Presentation Date & Time: Friday, October 25 at 5:15 PM ET
Location: Monitor 19, Exhibit Hall A - Correlation of Time to Treatment with Attack Duration in the Sebetralstat KONFIDENT Phase 3 Trial
Authors: Timothy J. Craig, Jonathan A. Bernstein, Hilary Longhurst, James Hao, Michael D. Smith, Paul K. Audhya, Christopher M. Yea, Marcus Maurer
Presentation Date & Time: Friday, October 25 at 5:30 PM ET
Location: Monitor 19, Exhibit Hall A
KalVista looks forward to sharing these important findings with attendees and contributing to the ongoing dialogue in the field of allergy, asthma, and immunology.
About Sebetralstat
Discovered and developed entirely by the scientific team at KalVista, sebetralstat is a novel, investigational oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (HAE). Sebetralstat received Fast Track and Orphan Drug Designations from the U.S. FDA, as well as Orphan Drug Designation and an approved Pediatric Investigational Plan from the European Medicines Agency (EMA).
About Hereditary Angioedema
Hereditary angioedema (HAE) is a rare genetic disease resulting in deficiency or dysfunction in the C1 esterase inhibitor (C1INH) protein and subsequent uncontrolled activation of the kallikrein-kinin system. People living with HAE experience painful and debilitating attacks of tissue swelling in various locations of the body that can be life-threatening depending on the location affected. All currently approved on-demand treatment options require either intravenous or subcutaneous administration.
